These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 25374315)
1. Intellectual property strategy for regenerative medicine: is it time to 'regenerate'? Komatani TS Pharm Pat Anal; 2014 Sep; 3(5):475-9. PubMed ID: 25374315 [No Abstract] [Full Text] [Related]
3. Intellectual property. Fixing the legal framework for pharmaceutical research. Knowles SM Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445 [No Abstract] [Full Text] [Related]
4. US Army Medical Command intellectual property. Arwine E; Caldwell J US Army Med Dep J; 2010; ():56-61. PubMed ID: 20467974 [No Abstract] [Full Text] [Related]
5. Science and the law. Working through the patent problem. Walsh JP; Cohen WM; Arora A Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928 [No Abstract] [Full Text] [Related]
6. Intellectual Property in the Field of Regenerative Medicine in Japan. Asano S; Nakanishi Y; Sugiyama D Clin Ther; 2018 Nov; 40(11):1823-1827. PubMed ID: 30458929 [TBL] [Abstract][Full Text] [Related]
7. An overview of a recent court challenge to the protection of biomarkers as intellectual property. Hall SC; Tromp JM; Jortani SA Clin Chim Acta; 2011 May; 412(11-12):802-5. PubMed ID: 21315704 [TBL] [Abstract][Full Text] [Related]
8. Welcome to the World Stem Cell Report. Siegel B Regen Med; 2011 Nov; 6(6 Suppl):1-2. PubMed ID: 21999254 [No Abstract] [Full Text] [Related]
9. Patenting for the research scientist: an update. Crespi RS Trends Biotechnol; 2004 Dec; 22(12):638-42. PubMed ID: 15542154 [TBL] [Abstract][Full Text] [Related]
10. Human induced pluripotent stem cells: a review of the US patent landscape. Georgieva BP; Love JM Regen Med; 2010 Jul; 5(4):581-91. PubMed ID: 20632861 [TBL] [Abstract][Full Text] [Related]
11. Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system. Kesselheim AS AAPS J; 2007 Aug; 9(3):E306-11. PubMed ID: 17915832 [TBL] [Abstract][Full Text] [Related]
12. Intellectual property and patent in stem cell research era. Kiatpongsan S J Med Assoc Thai; 2006 Nov; 89(11):1984-6. PubMed ID: 17205886 [TBL] [Abstract][Full Text] [Related]
13. California Institute for Regenerative Medicine: accelerating stem cell therapies in California and beyond. Trounson A Stem Cells Transl Med; 2012 Jan; 1(1):6-8. PubMed ID: 23197633 [No Abstract] [Full Text] [Related]
16. Science and law. View from the bench: patents and material transfers. Walsh JP; Cho C; Cohen WM Science; 2005 Sep; 309(5743):2002-3. PubMed ID: 16179461 [No Abstract] [Full Text] [Related]
17. Intellectual property protection for plant-related inventions in Europe. Fleck B; Baldock C Nat Rev Genet; 2003 Oct; 4(10):834-8. PubMed ID: 14526379 [TBL] [Abstract][Full Text] [Related]
18. The social production of evidence: regenerative medicine and the 21st Century Cures Act. Hogle LF; Das A Regen Med; 2017 Sep; 12(6):581-586. PubMed ID: 28976283 [No Abstract] [Full Text] [Related]
19. Science and law. Intellectual property and human embryonic stem cell research. Loring JF; Campbell C Science; 2006 Mar; 311(5768):1716-7. PubMed ID: 16556826 [No Abstract] [Full Text] [Related]
20. Upcoming challenges in intellectual property presented by emerging pharmaceutical technologies. Komatani TS Pharm Pat Anal; 2017 Jan; 6(1):1-4. PubMed ID: 28198642 [No Abstract] [Full Text] [Related] [Next] [New Search]